New biomarker shows potential to evaluate treatment response for metastatic colorectal cancer

Graphical abstract. Credit: Biomedicine & Pharmacotherapy (2024). DOI: 10.1016/j.biopha.2024.116857 Colorectal cancer is the second leading cause of cancer deaths worldwide and the third most diagnosed cancer, affecting over a million people annually. The problem worsens if the tumor is metastatic, meaning it moves from the original organ to other parts of the body. In this scenario, the five-year survival rate drops from 70–90% to just 10%. While some subgroups of colorectal cancer patients are beginning to have new therapeutic options, the vast majority of metastatic patients still follow conventional treatments, typically involving chemotherapy with biological agents. Initially effective, these treatments Read More